
Tetrahedron 67 (2011) 4612-4615

Contents lists available at ScienceDirect

Tetrahedron



Silver-catalyzed synthesis of disubstituted isoxazoles by cyclization of alkynyl oxime ethers

Masafumi Ueda, Yuki Ikeda, Aoi Sato, Yuta Ito, Maiko Kakiuchi, Hiroko Shono, Tetsuya Miyoshi, Takeaki Naito, Okiko Miyata*

Kobe Pharmaceutical University, Motoyamakita, Higashinada, Kobe 658-8558, Japan

ARTICLE INFO

Article history: Received 10 March 2011 Received in revised form 19 April 2011 Accepted 20 April 2011 Available online 29 April 2011

Keywords: Silver Isoxazole synthesis Oxime ether Alkyne

ABSTRACT

A facile and practical synthesis of 3,5-disubstituted isoxazoles via a silver-catalyzed cyclization and subsequent protonation of alkynyl oxime ethers has been developed. The methodology was successfully applied to the synthesis of a biologically active isoxazolecarboxylic acid.


© 2011 Elsevier Ltd. All rights reserved.

Tetrahedror

1. Introduction

Heterocycles are well known for their wide range of biological properties.¹ Among the various bioactive heterocycles, isoxazoles attract great interest because of their wide reaching applications in the medicinal chemistry² and material science.³ The vast majority of existing methodologies for the synthesis of isoxazoles^{4–9} rely on either the condensation of a hydroxylamine with a 1,3-dicarbonyl compound or α , β -unsaturated carbonyl compound,¹⁰ or the [3+2] cycloaddition reaction between an alkyne and a nitrile oxide.¹¹ These methods usually require harsh conditions and result in poor chemo- and regioselectivities. For this reason, research into novel and efficient methods for the synthesis of isoxazoles is continuously being pursued.¹²

The transition metal-catalyzed intramolecular addition of a heteroatom to an alkyne is one of the most powerful strategies for the synthesis of heterocyclic compounds.¹³ This area has, however, been less explored for isoxazoles.^{14–16} Recently, we have developed a methodology for the synthesis of trisubstituted isoxazoles **2** through a gold-catalyzed domino reaction of an alkynyl oxime ether, involving a 5-*endo-dig* cyclization and a subsequent Claisentype [3,3]-sigmatropic rearrangement (Scheme 1).¹⁷ We anticipated that the reaction in the presence of Brønsted acid would suppress the migration of substituent R³ and produce the 3,5-



Scheme 1. Transition metal-catalyzed synthesis of isoxazoles.

disubstituted isoxazoles **3**, via protonation of the vinyl metal intermediate **A**. Therefore, a switchable divergent synthesis of triand disubstituted isoxazoles can be accomplished by tuning the reaction conditions. Herein, we report an efficient and versatile methodology for the synthesis of 3,5-disubstituted isoxazoles, through the transition metal-catalyzed cyclization of alkynyl oxime ethers in connection with our recent explorations of the chemistry of conjugated imines.¹⁸

2. Results and discussion


Our studies commenced with a screening of catalysts (Table 1). (*Z*)-O-Benzyl alkynyl oxime ether **1a**, which was easily prepared by the condensation of 1,3-diphenylprop-2-yn-1-one with O-benzyl-hydroxylamine hydrochloride, was selected as a model substrate, since the benzyl group would act as a good leaving group.^{19,20} The



^{*} Corresponding author. Tel.: +81 78 4417554; fax: +81 78 4417556; e-mail address: miyata@kobepharma-u.ac.jp (O. Miyata).

^{0040-4020/\$ –} see front matter @ 2011 Elsevier Ltd. All rights reserved. doi:10.1016/j.tet.2011.04.083

Table 1Optimization of the cyclization reaction^a



Entry	Catalyst	Proton source	Solvent	Time (h)	Yield (%) ^b
1	AuCl ₃	PhOH	THF	24	23
2	AuCl(PPh ₃)	PhOH	THF	24	9
3	AgBF ₄	PhOH	THF	6	80
4	AgSbF ₆	PhOH	THF	24	32
5	$Cu(OTf)_2$	PhOH	THF	24	59
6	AgBF ₄	MeOH	THF	6	48 (50) ^c
7	AgBF ₄	AcOH	THF	2	71
8	AgBF ₄	PhOH	benzene	6	14
9	AgBF ₄	PhOH	toluene	1	39
10	AgBF ₄	none	THF	6	NR ^d
11	none	PhOH	THF	6	NR ^d


 $^{\rm a}$ Reaction conditions: 1a (0.16 mmol), 20 mol % of catalyst, 2.0 equiv of proton source, solvent (5 mL).

^b Yield of isolated product after chromatography.

^c Yield in parentheses is for the recovered starting material **1a**.

screening of various metal catalysts (20 mol %), in the presence of phenol as a proton source, in THF at reflux, revealed AgBF₄ to be optimal both for reaction time and yield (80%) (entries 1–5). We then examined different proton sources. MeOH led to low conversions into the corresponding 3,5-disubstituted isoxazole **3a** (48% yield) (entry 6). Although acetic acid could accelerate the silver-catalyzed cyclization reaction, the yield was lower, due to the formation of a decomposition product (entry 7). These results suggest that weakly acidic conditions are required. The reaction was strongly influenced by the choice of solvent, with benzene and toluene leading to decreased chemical yields of **3a** (entries 8 and 9). A control reaction, in the absence catalyst or proton source, did not lead to any conversion, confirming that these results are attributed predominantly to the silver-catalyzed and phenol-promoted reaction.

On the basis of the above results, a proposed mechanism is shown in Scheme 2. The addition of an oxygen atom to the Ag(I)-activated C–C triple bond, in 5-*endo-dig* fashion, generates an oxonium intermediate **C**. The protonation of **C** by phenol, and subsequent elimination of the benzyl cation produces **D**. The benzyl




Scheme 2. Proposed reaction pathway.

cation would undergo polymerization, since the formation of any benzyl phenyl ether was not observed in the reaction mixture. Finally, the aromatization of **D** affords isoxazole **3a** and liberates the catalytic silver species.

To examine the scope of the reaction, we treated various alkynyl oxime ethers **1b**-j with AgBF₄ and phenol, in refluxing THF, and obtained the corresponding disubstituted isoxazoles **3b**-**i** in moderate to good vield (Table 2). The cyclization reaction of **1b**, which had alkyl group on the triple bond terminus, proceeded to give 3b in good yield (entry 1). Interestingly, substrates 1c-e, bearing an oxygen functionality at the propargylic position (R^2) efficiently underwent the cyclization within 1 h to yield **3c–e** (entry 2–4). We propose that the chelation of the oxygen atom enhances the reactivity of catalyst. It is noteworthy that the unprotected hydroxyl group did not inhibit the course of the reaction (entry 4). Variation of the substituent at \mathbb{R}^1 was then examined using a substrate bearing the acetoxy group at the propargylic position. Both electron-rich and electron-poor aryl groups, and a hydrogen atom were readily accommodated, producing the expected disubstituted isoxazoles 3f-h and monosubstituted isoxazole 3i in good yield, respectively (entries 5-8). A notably high chemical yield was observed in the reaction of **1g**, which has a *p*-trifluoromethylphenyl group at \mathbb{R}^1 . An imino ester 1j was also employed in this reaction, affording isoxazole carboxylate 3j in high yield (entry 9).



Silver-catalyzed synthesis of disubstituted isoxazoles^a




Entry	Substrate	\mathbb{R}^1	R ²	Time (h)	Product	Yield (%) ^b
1	1b	Ph	n-Bu	6	3b	70
2	1c	Ph	CH ₂ OMe	1	3c	71
3	1d	Ph	CH ₂ OAc	1	3d	80
4	1e	Ph	CH ₂ OH	1	3e	65
5	1f	4-MeOC ₆ H ₄	CH ₂ OAc	1	3f	60
6	1g	$4-CF_3C_6H_4$	CH ₂ OAc	1	3g	86
7	1h	2-Furyl	CH ₂ OAc	1	3h	64
8	1i	Н	CO ₂ Et	7	3i	59
9	1j	CO ₂ Me	Ph	12	3j	81

 $^{\rm a}$ Reaction conditions: 1 (0.16 mmol), 20 mol % of catalyst, 2.0 equiv of phenol, THF (5 mL).

Yield of isolated product after chromatography.

To illustrate the potential utility of this reaction, we have examined its application to synthesis of the biologically active isoxazolecarboxylic acid **6**, which was synthesized by Ellman's group and found to be a strong *Mycobacterium tuberculosis* phosphatase PtpB inhibitor (Scheme 3).²¹ Unfortunately, their synthetic strategy for the synthesis of isoxazole ring, involving [3+2] cycloaddition reaction, was inefficient and resulted in a low yield. In contrast, our method was highly effective, as shown in Scheme 3. The cyclization



i) MeO₂CCOCI, Cul, Et₃N, THF, 61%. ii) BnONH₂·HCI, Pyridine, Na₂SO₄, MeOH, 60% iii) AgBF₄, Phenol, 1,4-dioxane, 75%. iv) 1M NaOH, THF, quant.

^d NR: no reaction.

of alkynyl oxime ether **5**, which was readily prepared from alkyne **4**, afforded desired isoxazolecarboxylate in 75% yield. We finally succeeded in the total synthesis of phosphatase PtpB inhibitor **6**, by hydrolyzing the ester with 1 M NaOH.

3. Conclusion

We have successfully developed a novel method for the synthesis of disubstituted isoxazoles from alkynyl oxime ethers via a silver-catalyzed cyclization and subsequent protonation with phenol. This protocol was successfully applied to the synthesis of a biologically active compound. The reaction is straightforward, and allows for the efficient construction of substituted isoxazoles.

4. Experimental section

4.1. General

NMR spectra were recorded at 300 MHz/75 MHz (¹H NMR/¹³C NMR) or 500 MHz/125 MHz (¹H NMR/¹³C NMR) using Varian Gemini-300 (300 MHz), Varian MERCURY plus 300 (300 MHz), or Varian NMR system AS 500 (500 MHz) spectrometers. Chemical shifts (δ) are reported as follows: chemical shift, multiplicity (s=singlet, d=doublet, t=triplet, q=quartet, quint=quintet, sext=sextet, m=multiplet, br=broad), coupling constants, and integration. IR spectra were obtained on a Perkin–Elmer SpectrumOne A spectrometer. Mass spectra were obtained by EI, CI or ESI methods on a Hitachi M-4100 and Thermo Fisher Scientific Exactive. Preparative TLC separations (PTLC) were carried out on pre-coated silica gel plates (E. Merck 60F₂₅₄). THF was freshly distilled from benzophenone ketyl radical anion prior to use.

4.2. General procedure for the silver-catalyzed synthesis of disubstituted isoxazole 3

To a solution of alkynyl oxime ether **1** (0.15 mmol) in THF (5 mL) were added phenol (28 mg, 0.3 mmol) and AgBF₄ (5.8 mg, 0.03 mmol), with a drying tube filled with silica gel at room temperature. After being stirred at reflux for 1–12 h (TLC monitoring), the reaction mixture was concentrated under reduced pressure. The residue was purified by preparative TLC (hexane/AcOEt=3–10:1) to afford isoxazole **3**. The physical and spectroscopic data of **3a**⁵ and **3j**^{12h} were in accord with those reported in the literature.

4.2.1. 5-Butyl-3-phenylisoxazole (**3b**). A colorless oil. ¹H NMR (CDCl₃, 300 MHz) δ : 7.81–7.78 (2H, m), 7.46–7.41 (3H, m), 6.28 (1H, d, *J*=0.5 Hz), 2.85 (2H, t, *J*=7.5 Hz), 1.73 (2H, quint, *J*=7.5 Hz), 1.43 (2H, sext, *J*=7.5 Hz), 0.96 (3H, t, *J*=7.5 Hz). ¹³C NMR (CDCl₃, 75 MHz) δ : 174.3, 162.3, 129.7, 129.4, 128.8, 126.7, 98.7, 29.6, 26.5, 22.2, 13.7. HRMS *m/z*: calcd for C₁₃H₁₅NO (M⁺) 201.1153. Found: 201.1156.

4.2.2. 5-(*Methoxymethyl*)-3-*phenylisoxazole* (**3c**). A colorless oil. ¹H NMR (CDCl₃, 300 MHz) δ : 7.83–7.79 (2H, m), 7.47–7.44 (3H, m), 6.58 (1H, t, *J*=0.5 Hz), 4.60 (2H, s), 3.48 (3H, s). ¹³C NMR (CDCl₃, 75 MHz) δ : 169.8, 162.4, 130.0, 128.9, 126.80, 126.76, 100.9, 65.4, 58.9. HRMS *m*/*z*: calcd for C₁₁H₁₁NO₂ (M⁺) 189.0790. Found: 189.0802.

4.2.3. Acetic acid (3-phenyl-5-isoxazolyl)methyl ester (**3d**). A colorless oil. IR (NaCl) cm⁻¹: 1750. ¹H NMR (CDCl₃, 300 MHz) δ : 7.82–7.79 (2H, m), 7.47–7.45 (3H, m), 6.63 (1H, d, *J*=0.5 Hz), 5.23 (2H, d, *J*=0.5 Hz), 2.15 (3H, s). ¹³C NMR (CDCl₃, 75 MHz) δ : 170.1, 167.1, 162.5, 130.1, 128.9, 128.6, 126.7, 102.1, 56.3, 20.5. HRMS *m/z*: calcd for C₁₂H₁₁NO₃ (M⁺) 217.0738. Found: 217.0752.

4.2.4. 3-Phenyl-5-isoxazolylmethanol (**3e**). A colorless solid. 1 H NMR (CDCl₃, 300 MHz) δ : 7.82–7.79 (2H, m), 7.47–7.45 (3H, m),

6.58 (1H, s), 4.84 (2H, s), 2.08 (1H, s). ¹³C NMR (CDCl₃, 75 MHz) δ : 171.9, 162.5, 130.1, 128.9, 128.8, 126.8, 100.0, 56.6, 26.4. HRMS *m*/*z*: calcd for C₁₀H₉NO₂ (M⁺) 175.0633. Found: 175.0633.

4.2.5. Acetic acid [3-(4-Methoxyphenyl)-5-isoxazolyl]methyl ester (**3***f*). A colorless oil. IR (NaCl) cm⁻¹: 1744. ¹H NMR (CDCl₃, 300 MHz) δ : 7.75–7.72 (2H, m), 6.99–6.96 (2H, m), 6.56 (1H, s), 5.21 (2H, s), 3.85 (3H, s), 2.14 (3H, s). ¹³C NMR (CDCl₃, 75 MHz) δ : 170.2, 166.9, 162.1, 161.1, 128.2, 121.2, 114.3, 102.0, 56.4, 35.3, 20.6. HRMS *m*/*z*: calcd for C₁₃H₁₃NO₄ (M⁺) 247.0844. Found: 247.0866.

4.2.6. Acetic acid [3-[4-(Trifluoromethyl)phenyl]-5-isoxazolyl]methyl ester (**3g**). A colorless oil. IR (NaCl) cm⁻¹: 1745. ¹H NMR (CDCl₃, 300 MHz) δ : 7.93 (2H, dd, J=8.5, 0.5 Hz), 7.73 (2H, dd, J=8.5, 0.5 Hz), 6.67 (1H, s), 5.25 (2H, d, J=0.5 Hz), 2.16 (3H, s). ¹³C NMR (CDCl₃, 125 MHz) δ : 170.2, 167.9, 161.4, 132.0 (q, J=33 Hz), 127.1, 125.9 (q, J=3.6 Hz), 123.8 (q, J=271 Hz), 102.2, 56.3, 20.6. HRMS *m/z*: calcd for C₁₃H₁₀F₃NO₃ (M⁺) 285.0612. Found: 285.0625.

4.2.7. Acetic acid [3-(2-furanyl)-5-isoxazolyl]methyl ester (**3h**). A colorless oil. IR (NaCl) cm⁻¹: 1748. ¹H NMR (CDCl₃, 300 MHz) δ : 7.56 (1H, dd, *J*=2.0, 1.0 Hz), 6.92 (1H, dd, *J*=3.5, 1.0 Hz), 6.58 (1H, s), 6.53 (1H, dd, *J*=3.5, 2.0 Hz), 5.21 (2H, s), 2.14 (3H, s). ¹³C NMR (CDCl₃, 125 MHz) δ : 170.2, 167.9, 161.4, 127.1, 125.99, 125.96, 125.93, 125.90, 102.2, 56.3, 20.6. HRMS *m*/*z*: calcd for C₁₃H₁₀F₃NO₃ (M⁺) 285.0612. Found: 285.0625.

4.2.8. 5-Isoxazolecarboxylic acid ethyl ester (**3i**). A colorless oil. IR (NaCl) cm⁻¹: 1735. ¹H NMR (CDCl₃, 300 MHz) δ : 8.37 (1H, d, *J*=2.0 Hz), 6.96 (1H, d, *J*=2.0 Hz), 4.45 (2H, q, *J*=7.0 Hz), 1.43 (3H, t, *J*=7.0 Hz). ¹³C NMR (CDCl₃, 125 MHz) δ : 160.1, 156.7, 150.6, 108.7, 77.2, 62.3, 14.1. HRMS *m*/*z*: calcd for C₆H₇NO₃ (M⁺) 141.0425. Found: 141.0427.

4.3. Synthesis of isoxazolecarboxylic acid 6

4.3.1. 4-[3-Cyclohexyl-4'-fluoro-3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-butynoic acid methyl ester. To a solution of CuI (14 mg, 0.072 mmol) in THF (5 mL) were added Et₃N (0.4 mL, 2.89 mmol), a solution of alkyne $\mathbf{4}^{21a}$ (100 mg, 1.44 mmol) in THF (2 mL) and methyl chloroglyoxalate (0.27 mL, 2.89 mmol), under an Ar atmosphere at room temperature. After being stirred at the same temperature for 15 h, the reaction mixture was diluted with H₂O and extracted with Et₂O. The organic phase was dried over MgSO₄ and concentrated under reduced pressure. Purification by PTLC (hexane/ AcOEt=8:1) afforded ketoester (76 mg, 61%) as a colorless solid. IR (NaCl) cm⁻¹: 2191, 1744, 1674. ¹H NMR (CDCl₃, 500 MHz) δ: 7.81–7.72 (3H, m), 7.48 (1H, d, J=2.0 Hz), 7.41 (1H, dd, J=8.0, 2.0 Hz), 7.31 (1H, t, J=9.0 Hz), 3.99 (3H, s), 3.26–3.21 (1H, m), 1.97–1.81 (4H, m), 1.57–1.47 (4H, m), 1.33–1.25 (2H, m). ¹³C NMR (CDCl₃, 125 MHz) δ : 168.9, 160.8, 159.7, 158.7, 154.1, 142.5, 136.73, 136.70, 135.7, 132.7, 132.6, 126.0, 124.8, 124.7, 117.73, 117.68, 117.5, 97.0, 91.7, 53.7, 42.4, 33.8, 26.7, 26.0. HRMS m/z: calcd for C₂₄H₂₀O₃F₄(M⁺) 432.1347. Found: 432.1371.

4.3.2. 4-[3-Cyclohexyl-4'-fluoro-3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-[(phenylmethoxy)imino]-3-butynoic acid methyl ester (**5**). To a solution of alkynyl ketone (47 mg, 0.11 mmol) in MeOH (2 mL) were added *O*-benzylhydroxylamine hydrochloride (35 mg, 0.22 mmol), Na₂SO₄ (31 mg, 0.22 mmol), and pyridine (0.2 mL), under an N₂ atmosphere at room temperature. After being stirred at the same temperature for 2 h, the reaction mixture was diluted with H₂O and extracted with Et₂O. The organic phase was washed with brine, dried over MgSO₄, and concentrated under reduced pressure. Purification by PTLC (benzene) afforded **5** (42 mg 71%) as a colorless solid. IR (NaCl) cm⁻¹: 2202, 1736, 1622. ¹H NMR (CDCl₃, 500 MHz) δ : 7.78–7.72 (2H, m), 7.61 (1H, d, *J*=8.0 Hz), 7.45–7.28 (3H, m,), 5.47 (2H, s), 3.95 (3H, s), 3.15 (1H, tt, J=12.0, 3.0 Hz), 1.92–1.89 (2H, m), 1.80–1.77 (2H, m), 1.71–1.69 (1H, m), 1.47–1.39 (2H, m), 1.35–1.20 (3H, m). ¹³C NMR (CDCl₃, 125 MHz) δ : 161.6, 160.5, 158.4, 151.8, 140.5, 137.15, 137.12, 136.1, 134.1, 133.9, 132.52, 132.45, 128.6, 128.43, 128.40, 125.81, 125.79, 124.4, 124.3, 120.2, 117.5, 117.3, 101.6, 82.5, 79.0, 53.2, 42.1, 33.6, 26.7, 26.1. HRMS *m*/*z*: calcd for C₃₁H₂₇NO₃F₄ (M⁺) 537.1925. Found: 537.1941.

4.3.3. 5-[3-Cyclohexyl-4'-fluoro-3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-3-isoxazolecarboxylic acid methyl ester. To a solution of alkynyl oxime ether 5 (42 mg, 0.078 mmol) in 1,4-dioxane (5 mL) were added phenol (15 mg, 0.16 mmol) and AgBF₄ (15 mg, 0.078 mmol), with a drying tube filled with silica gel at room temperature. After being stirred at reflux for 7 days, the reaction mixture was filtered with SiO_2 and concentrated under reduced pressure. Purification by PTLC (benzene) afforded isoxazole carboxylate (27 mg, 75%) as a colorless solid. IR (NaCl) cm⁻¹: 1741. ¹H NMR (CDCl₃, 500 MHz) δ: 7.82–7.76 (2H, m), 7.64 (1H, d, J=8.0 Hz), 7.57 (1H, d, J=2.0 Hz), 7.46 (1H, dd, J=8.0, 2.0 Hz), 7.31 (1H, t, J=9.0 Hz), 6.80 (1H, s), 4.04 (3H, s), 2.90 (1H, tt, J=11.5, 3.0 Hz), 1.92–1.77 (5H, m), 1.58–1.26 (5H, m). ¹³C NMR (125 MHz) δ: 172.0, 160.5, 156.4, 147.6, 141.3, 136.97, 136.94, 132.6, 132.5, 130.4, 125.91, 125.88, 125.7, 125.2, 124.8, 117.6, 103.6, 53.0, 40.8, 34.4, 26.7, 26.0. HRMS *m*/*z*: calcd for C₂₄H₂₁NO₃F₄ (M⁺) 447.1467. Found: 447.1475.

4.3.4. 5-[3-Cyclohexyl-4'-fluoro-3'-(trifluoromethyl)[1,1'-biphenyl]-4-vll-3-isoxazolecarboxvlic acid (6). To a solution of isoxazole carboxylate (27 mg, 0.06 mmol) in THF (1 mL) was added 1 M NaOH (1 mL), under N₂ at room temperature. After being stirred at the same temperature for 1 h, the reaction mixture was concentrated under reduced pressure, diluted with 2 M HCl and extracted with AcOEt. The organic layer was washed with 2 M HCl, washed with brine, dried over MgSO₄, and concentrated under reduced pressure to give **1** (26 mg, quant) as a colorless solid. IR (NaCl) cm⁻¹: 1719. ¹H NMR (CDCl₃/CD₃OD (1:1), 500 MHz) δ: 7.83–7.80 (2H, m), 7.66 (1H, d, J=8.0 Hz), 7.59 (1H, s), 7.49 (1H, dd, J=8.0, 1.5 Hz), 7.34 (1H, t, J=9.0 Hz), 6.82 (1H, s), 2.94–2.89 (1H, m), 1.89 (3H, t, J=14.5 Hz), 1.79 (1H, d, J=12.0 Hz), 1.56 (2H, q, J=12.0 Hz), 1.45-1.25 (4H, m). ¹³C NMR (CDCl₃/CD₃OD (1:1), 125 MHz) δ: 171.6, 161.4, 157.1, 147.3, 141.0, 136.78, 136.75, 132.5, 132.4, 130.1, 125.6, 125.4, 125.1, 124.5, 117.3, 117.2, 103.6, 40.6, 34.1, 26.4, 25.7. HRMS m/z: calcd for C₂₃H₂₀NO₃F₄ (M⁺) 434.1378. Found: 434.1387. The spectroscopic data are consistent with those reported in the literature.^{21a}

Acknowledgements

This work was supported by Grants-in Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and the Research Foundation for Pharmaceutical Sciences.

Supplementary data

These data include experimental procedures for the synthesis of alkynyl oxime ethers **1a**–**h** and **1j**. Supplementary data related to this article can be found online at doi:10.1016/j.tet.2011.04.083.

References and notes

- 1. Katritzky, A. R.; Ramsden, C. A.; Scriven, E. F. V.; Taylor, R. J. K.; Joule, J. Comprehensive Heterocyclic Chemistry III; Elsevier: Oxford, 2008.
- (a) Carlsen, L.; Döpp, D.; Döpp, H.; Duus, F.; Hartmann, H.; Lang-Fugmann, S.; Schulze, B.; Smalley, R. K.; Wakefield, B. J. In *Houben-weyl Methods in Organic Chemistry*; Schaumann, E., Ed.; Georg Thieme: Stuttgart, 1992; Vol. E8a, p 45; (b) Sperry, J.; Wright, D. *Curr. Opin. Drug Discovery Dev.* **2005**, *8*, 723.
- 3. Lee, Y.; Koyama, Y.; Yonekawa, M.; Tanaka, T. Macromolecules 2009, 42, 7709.
- For review, see: Wakefield, B. J. In Science of Synthesis: Houben-weyl Methods of Molecular Transformations; Shaumann, E., Ed.; Georg Thieme: Stuttgart, 2001; Vol. 11, p 229.
- 5. Dang, T. T.; Albrecht, U.; Langer, P. Synthesis 2006, 2515.
- 6. Wang, K.; Xiang, D.; Liu, J.; Pan, W.; Dong, D. Org. Lett. 2008, 10, 1691.
- 7. Li, X.; Du, Y.; Liang, Z.; Li, X.; Pan, Y.; Zhao, K. Org. Lett. 2009, 11, 2643.
- 8. Gaywood, A. P.; McNab, H. J. Org. Chem. 2009, 74, 4278.
- Girardin, M.; Alsabeh, P. G.; Lauzon, S.; Dolman, S. J.; Ouellet, S. G.; Hughes, G. Org. Lett. 2009, 11, 1159.
- (a) Tang, S.; He, J.; Sun, Y.; He, L.; She, X. Org. Lett. 2009, 11, 3982; (b) Ahmed, M.
 S. M.; Kobayashi, K.; Mori, A. Org. Lett. 2005, 7, 4487; (c) Ghosh, T.; Bandyopadhyay, C. Tetrahedron Lett. 2004, 45, 6169; (d) Cuadrado, P.; Gonzalez-Nogal, A. M.; Valero, R. Tetrahedron 2002, 58, 4975.
- For review, see: Jäger, V.; Colinas, P. A. In Synthetic Applications of 1,3-Dipolar Cycloaddition Chemistry toward Heterocycles and Natural Products; Padwa, A., Ed.; Wiley: Hoboken, 2002; Vol. 59, p 361.
- For a recent study on the synthesis of disubstituted isoxazoles, see: (a) Debleds, O.; Gayon, E.; Ostaszuk, E.; Vrancken, E.; Campagne, J.-M. Chem.—Eur, J. 2010, 16, 12207; (b) Tang, S.; He, J.; Sun, Y.; He, L.; She, X. J. Org. Chem. 2010, 75, 1961; (c) Conti, P.; Pinto, A.; Tamborini, L.; Dunkel, P.; Gambaro, V.; Viscoti, G. L.; Micheli, C. D. Synthesis 2009, 591; (d) Bhosale, S.; Kurhade, S.; Prasad, U. V.; Palle, V. P.; Bhuniya, D. Tetrahedron Lett. 2009, 50, 3948; (e) McClendon, E.; Omollo, A. O.; Valente, E. J.; Hamme, A. T., II. Tetrahedron Lett. 2009, 50, 533; (f) Grecian, S.; Fokin, V. V. Angew. Chem. Int. Ed. 2008, 47, 8285; (g) Willy, B.; Rominger, F.; Muller, T. J. J. Synthesis 2008, 293; (h) Hansen, T. V.; Wu, P.; Fokin, V. V. J. Org. Chem. 2005, 70, 7761.
- (a) Lipshutz, B. H.; Yamamoto, Y. Chem. Rev. 2008, 108, 3239; (b) Kirsch, S. F. Synthesis 2008, 3183.
- 14. Perumal's group reported a gold-catalyzed synthesis of disubstituted isoxazoles from α,β-acetylenic oximes, which were prepared by the condensation of hydroxylamine with alkynyl ketones. Praveen, C.; Kalyanasundaram, A.; Perumal, P. T. Synlett **2010**, 777 However, the preparation of the α,β-acetylenic oximes suffer from poor reproducibility and the formation of undesired 4,5-dihydroisoxazol-5-ol, by a 1,4-addition of hydroxylamine and cyclization ¹⁵.
- (a) Marei, M. G.; Ghonaim, R. A. Indian J. Chem. 1993, 32B, 418; (b) Marei, M. G.; El-Ghanam, M. Bull. Chem. Soc. Jpn. 1992, 65, 3509; (c) Linderman, R. J.; Kirollos, K. S. Tetrahedron Lett. 1989, 30, 2049; (d) Linderman, R. J.; Lonikar, M. S. J. Org. Chem. 1988, 53, 6013.
- For the synthesis of dihydroisoxazoles, see: (a) Winter, C.; Krause, N. Angew. Chem., Int. Ed. 2009, 48, 6339; (b) Debleds, O.; Zotto, C. D.; Vrancken, E.; Campagne, J.-M.; Retailleau, P. Adv. Synth. Catal. 2009, 351, 1991.
- Ueda, M.; Sato, A.; Ikeda, Y.; Miyoshi, T.; Naito, T.; Miyata, O. Org. Lett. 2010, 12, 2594.
- (a) Ueda, M.; Matsubara, H.; Yoshida, K.; Sato, A.; Naito, T.; Miyata, O. Chem. —Eur. J. 2011, 17, 1789; (b) Ueda, M.; Miyabe, H.; Torii, M.; Kimura, T.; Miyata, O.; Naito, T. Synlets 2010, 1341; (c) Ueda, M.; Iwasada, E.; Miyabe, H.; Miyata, O.; Naito, T. Synletsis 2010, 1999; (d) Ueda, M.; Miyabe, H.; Kimura, T.; Kondoh, E.; Naito, T.; Miyata, O. Org. Lett. 2009, 11, 4632; (e) Rahaman, H.; Ueda, M.; Miyata, O.; Naito, T. Org. Lett. 2009, 11, 2651; (f) Ueda, M.; Miyabe, H.; Shimizu, H.; Sugino, H.; Miyata, O.; Naito, T. Angew. Chem., Int. Ed. 2008, 47, 5600; (g) Ueda, M.; Miyabe, H.; Sugino, H.; Miyata, O.; Naito, T. Angew. Chem., Int. Ed. 2005, 44, 6190.
- Larock recently reported the synthesis of 4-haloisoxazoles through the electrophilic cyclization of O-methyl alkynyl oxime ethers, see: (a) Waldo, J. P.; Mehta, S.; Neuenswander, B.; Lushington, G. H.; Larock, R. C. J. Comb. Chem. 2008, 10, 658; (b) Waldo, J. P.; Larock, R. C. J. Org. Chem. 2007, 72, 9643; (c) Waldo, J. P.; Larock, R. C. Org. Lett. 2005, 7, 5203.
- The silver-catalyzed cyclization also took place by using O-methyl alkynyl oxime ether as a substrate.
- (a) Soellner, M. B.; Rawls, K. A.; Grundner, C.; Alber, T.; Ellman, J. A. J. Am. Chem. Soc. 2007, 129, 9613; (b) Rawls, K. A.; Grundner, C.; Ellman, J. A. Org. Biomol. Chem. 2010, 8, 4066.